Tudor Investment Corp ET AL Lowers Stock Holdings in Bioventus Inc. (NYSE:BVS)

Tudor Investment Corp ET AL decreased its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 17.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 211,304 shares of the company's stock after selling 45,830 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.26% of Bioventus worth $2,219,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Tower Research Capital LLC TRC boosted its stake in shares of Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after acquiring an additional 1,786 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in Bioventus during the 4th quarter worth $38,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Bioventus during the fourth quarter worth $75,000. Quantbot Technologies LP acquired a new stake in shares of Bioventus in the fourth quarter valued at about $103,000. Finally, Arizona State Retirement System purchased a new position in shares of Bioventus in the fourth quarter worth about $109,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th. Craig Hallum set a $15.00 price objective on Bioventus and gave the stock a "buy" rating in a research report on Wednesday.

Bioventus Stock Performance

BVS stock remained flat at $6.80 during trading on Friday. 148,558 shares of the company's stock were exchanged, compared to its average volume of 451,347. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock has a market cap of $557.22 million, a price-to-earnings ratio of -11.15 and a beta of 0.95. The stock has a 50-day simple moving average of $8.47 and a 200 day simple moving average of $10.14. Bioventus Inc. has a one year low of $4.51 and a one year high of $14.38.

Insider Transactions at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,479 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the transaction, the chief financial officer now owns 131,963 shares of the company's stock, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,208 shares of company stock worth $226,138 in the last 90 days. Insiders own 32.90% of the company's stock.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.